What was the market valuation of pemphigus vulgaris in 2024?

The market valuation of pemphigus vulgaris was $419.11 Million in 2024. Read More

What is the projected market valuation for pemphigus vulgaris by 2035?

The projected market valuation for pemphigus vulgaris is $966.0 Million by 2035. Read More

What is the expected CAGR for the pemphigus vulgaris market during 2025 - 2035?

The expected CAGR for the pemphigus vulgaris market during 2025 - 2035 is 7.89%. Read More

Which companies are key players in the pemphigus vulgaris market?

Key players in the pemphigus vulgaris market include Roche, Bristol-Myers Squibb, Novartis, Amgen, Sanofi, Merck & Co., GSK, AbbVie, and Pfizer. Read More

What are the main treatment types for pemphigus vulgaris and their market values?

The main treatment types include Corticosteroids ($150.0 - $350.0 Million), Immunosuppressants ($120.0 - $250.0 Million), Monoclonal Antibodies ($100.0 - $250.0 Million), and Plasmapheresis ($49.11 - $116.0 Million). Read More

How is the pemphigus vulgaris market segmented by route of administration?

The market is segmented by route of administration into Oral ($167.11 - $392.0 Million), Intravenous ($167.0 - $392.0 Million), and Topical ($85.0 - $182.0 Million). Read More

What are the market values for different patient age groups in the pemphigus vulgaris market?

The market values for patient age groups are Pediatric ($50.0 - $120.0 Million), Adult ($250.0 - $600.0 Million), and Geriatric ($119.11 - $246.0 Million). Read More

What distribution channels are utilized in the pemphigus vulgaris market?

Distribution channels include Hospital Pharmacy ($167.64 - $384.0 Million), Online Pharmacy ($83.82 - $192.0 Million), and Retail Pharmacy ($167.65 - $390.0 Million). Read More

How does the market for pemphigus vulgaris appear to be evolving?

The market for pemphigus vulgaris appears to be evolving positively, with a projected increase in valuation and a robust CAGR of 7.89% during 2025 - 2035. Read More

What implications do the market trends have for future investments in pemphigus vulgaris treatments?

The upward trends in market valuation and growth suggest that future investments in pemphigus vulgaris treatments may be promising, particularly with the involvement of major pharmaceutical companies. Read More

US Pemphigus Vulgaris Market

ID: MRFR/Pharma/17397-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Pemphigus Vulgaris Market Research Report By Treatment Type (Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Plasmapheresis), By Route of Administration (Oral, Intravenous, Topical), By Patient Age Group (Pediatric, Adult, Geriatric) and By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Growth & Industry Forecast 2025 To 2035

US Pemphigus Vulgaris Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Treatment Type (USD Million)
  1. 4.1.1 Corticosteroids
  2. 4.1.2 Immunosuppressants
  3. 4.1.3 Monoclonal Antibodies
  4. 4.1.4 Plasmapheresis
2. 4.2 Food, Beverages & Nutrition, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Topical
3. 4.3 Food, Beverages & Nutrition, BY Patient Age Group (USD Million)
  1. 4.3.1 Pediatric
  2. 4.3.2 Adult
  3. 4.3.3 Geriatric
4. 4.4 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacy
  2. 4.4.2 Online Pharmacy
  3. 4.4.3 Retail Pharmacy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Amgen (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 GSK (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY PATIENT AGE GROUP
5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TREATMENT TYPE, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY PATIENT AGE GROUP, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Treatment Type (USD Million, 2025-2035)

Corticosteroids
Immunosuppressants
Monoclonal Antibodies
Plasmapheresis

Food, Beverages & Nutrition By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Topical

Food, Beverages & Nutrition By Patient Age Group (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Food, Beverages & Nutrition By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”